Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 12, 2008, Pages 1699-1705

  Moradian, Siamak ^a,b   Ahmadieh, Hamid ^a   Malihi, Mohsen ^a   Soheilian, Masoud ^a   Dehghan, Mohammad Hossein ^a   Azarmina, Mohsen ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Active progressive PDR; Fibrovascular tissue; Intravitreal bevacizumab; Vitreous hemorrhage

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENDOPHTHALMITIS; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSIVE DIABETIC RETINOPATHY; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; VITREOUS HEMORRHAGE; YOUNG ADULT;

EID: 56049104902     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0914-4     Document Type: Article

References (18)

1. Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB (1991) Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretianl photocoagulation. Ophthalmology 98:1575-1579
2. The Diabetic Retinopathy Vitrectomy Study Research Group (1985) Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 103:1643-1644
3. The Diabetic Retinopathy Vitrectomy Study Research Group (1988) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision, results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology 95:1307-1320
4. Comer GM, Ciulla TA (2004) Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 15:508-518, doi: 10.1097/01.icu.0000143685.60479.3b
5. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S et al (2000) The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care 23:504-509, doi: 10.2337/ diacare.23.4.504
6. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE (2001) Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300-306, doi: 10.1055/s-2001-15282
7. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611, doi: 10.1210/er.2003-0027
8. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-118, doi: 10.1097/ 00006982-200502000-00001
9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, doi: 10.1056/NEJM199412013312203
10. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964-970
11. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J et al (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66-71
12. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695-1705 doi: 10.1016/j.ophtha.2006.05.064
13. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278, doi: 10.1097/00006982-200603000-00004
14. Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98:823-833
15. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU (2006) Intravitreal Bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26(9):1006-1013, doi: 10.1097/ 01.iae.0000246884.76018.63
16. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352-354, doi: 10.1097/00006982-200603000-00016
17. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213-216, doi: 10.1136/bjo.2007.127142
18. Davidorf FH, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis Iridis from a single bevacizumab injection. Retina 26:354-356, doi: 10.1097/00006982-200603000-00017